Purpose An estimated 2.2 billion people are visually impaired worldwide. Given that age-
related vision loss is a primary cause of vision impairment, this number is projected to rise …

Treatment options for retinal diseases, such as neovascular age-related macular
degeneration, diabetic retinopathy, and retinal vascular disorders, have markedly expanded …

Purpose To describe outcomes 5 years after initiating treatment with bevacizumab or
ranibizumab for neovascular age-related macular degeneration (AMD). Design Cohort …

Topic Systematic review of risk factors for nonadherence and nonpersistence to intravitreal
anti–vascular endothelial growth factor (VEGF) injection therapy for neovascular age-related …

In the wake of rapid advances in automatic affect analysis, commercial automatic classifiers
for facial affect recognition have attracted considerable attention in recent years. While …

Clinical trials identified intravitreal vascular endothelial growth factor inhibitors (anti-VEGF
agents) have the potential to stabilise or even improve visual acuity outcomes in …

Purpose To evaluate associations of morphologic features with 5-year visual acuity (VA) in
the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Design …

Age-related macular degeneration (AMD) is the leading cause of visual impairment in the
aging population with a limited understanding of its pathogenesis and the number of …

Objectives To evaluate clinical characteristics of eyes in which investigator-determined new-
onset exudative age-related macular degeneration (eAMD) developed during the FILLY trial …

Importance To our knowledge, this is the first randomized clinical trial to compare visual
outcomes and injection loads between ranibizumab and aflibercept using an identical treat …